OTCM
KOAN
Market cap117kUSD
Jul 09, Last price
0.00USD
1D
0.00%
1Q
-66.67%
Jan 2017
-45.45%
Name
Resonate Blends Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
APOLLO BioWellness Inc. focuses its efforts on researching, formulating, and bringing to market products designed for human health within the regenerative medicine sector. A significant part of its operations involves the commercialization of licensed, naturally derived compounds currently awaiting patent approval, which are specifically engineered to boost an individual's innate capacity to mobilize adult stem cells from their own bone marrow. Additionally, the firm possesses the marketing rights for an all-natural, two-pronged dietary supplement crafted to help regulate hunger by engaging the body's intrinsic signaling pathways between the brain and the digestive system. Beyond its current offerings, the company is also deeply involved in research and development initiatives. These efforts are dedicated to exploring new frontiers, such as Secretogues aimed at enhancing a person's endogenous growth hormone synthesis, along with other natural bioactive formulations intended to optimize human physiological performance. This is achieved by harnessing the body's own biological mechanisms, entirely without the use of pharmaceutical drugs. The company maintains its corporate headquarters in North Bergen, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||